Kailera Therapeutics, Inc. Common Stock (KLRA · NASDAQ)

KLRA · MARKET VIEW

Market view · as of Sep 7, 2026

Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-1.09
vs $-0.74 est · miss
52-wk position
7.8%
-37.6% vs 52w high · -13.0% 1mo

Price (last ~year)

Shares of clinical-stage biotechnology firm Kailera Therapeutics (KLRA) recently traded at $16.23, down 15.2% over the last three months, despite new institutional investments from Atlas Venture and Wellington Management disclosed in the second quarter. The company, which has a $2.10 billion market capitalization and no revenue to date, reported a net loss of $111.3 million for the quarter ending June 30, 2026. It currently holds $130.3 million in cash against $10.2 million in debt.

Valuation

Market cap
$2.10B
P/B
1.825
Analyst target
$42.4

Quality & returns

Operating margin
0.0%
Profit margin
0.0%
ROE
-36.9%
ROA
-22.7%

Price movement

Last
$16.23
1-month
-13.0%
3-month
-15.2%
RSI (14)
39
vs SMA200
-19.8%
52-wk position
7.8% -37.6% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$0$-121.4M$-111.3M$-111.3M
2026-03-31$0$-84.7M$-78.9M$-84.6M
2025-06-30$0$-30.7M$-28.9M$0
2025-03-31$0$-20.5M$-18.0M$0

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots